Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey MUMBAI, India, Aug. 26, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global...